Harnessing Nanoparticles for Immunomodulation and Vaccines.

Gomes, Ariane C; Mohsen, Mona; Bachmann, Martin (2017). Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines, 5(1) MDPI 10.3390/vaccines5010006

Preview

Text vaccines-05-00006.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. The great interest in NPs is likely not only a result of the two successful vaccines against hepatitis B and Human Papilloma Virus (HPV) that use this technology, but also due to the versatility of those small-sized particles, as indicated by the wide range of applications reported so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems.

Interest & Impact

Downloads

356 since deposited on 13 Mar 2018
14 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item